Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIC and Umbilical Cord Blood Transplant in Hematologic Malignancies
NCT01622556Phase 2Terminated
- Sponsor
- University of Virginia
- Start
- Jan 2012
- Primary completion
- Feb 2014
- Modality
- Hematopoietic Stem Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of umbilical cord blood in Chronic Myeloid Leukemia (CML), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and 4 more, sponsored by University of Virginia. Primary endpoint: Event Free Survival at 180 days. Started Jan 2012; status: terminated.
02
Drugs
umbilical cord blood
03
Conditions
Chronic Myeloid Leukemia (CML)acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT01622556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01622556.